Samsung Bioepis Archives -

Recent rumours that Biogen was about to acquired by Samsung proved unfounded, but it turns out a deal

Biogen exits biosimilar JV with Samsung, raising $2.3bn

https://pharmaphorum.com/news/biogen-exits-biosimilar-jv-with-samsung-raising-2-3bn/

FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis

Phil Taylor age-related macular degeneration, Biogen, Byooviz, Lucentis, ophthalmology, regulatory approval, Roche, Samsung Bioepis 0 Comment

Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis’

FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis

https://pharmaphorum.com/news/fda-oks-first-biosimilar-of-roches-blockbuster-amd-drug-lucentis/

News/ News/ Sales and Marketing

Europe has its first Lucentis biosimilar, Samsung Bioepis’ Byooviz

Phil Taylor biosimilar, Byooviz, Lucentis, Novartis, ophthalmology, Roche, Samsung Bioepis, wet AMD 0 Comment

Novartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission

Europe has its first Lucentis biosimilar, Samsung Bioepis’ Byooviz

https://pharmaphorum.com/news/europe-has-its-first-lucentis-biosimilar-samsung-bioepis-byooviz/

Market Access/ News/ News

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

Richard Staines Biogen, biosimilars, market access, Novartis, ophthalmology, Samsung Bioepis 0 Comment

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

https://pharmaphorum.com/news/novartis-lucentis-could-face-biosimilar-competition/

News/ News/ Oncology

FDA approves Samsung/Merck & Co’s Herceptin biosimilar

Richard Staines biosimilar, breast cancer, Merck & Co, Samsung Bioepis 0 Comment

The FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck

FDA approves Samsung/Merck & Co’s Herceptin biosimilar

https://pharmaphorum.com/news/fda-approves-samsung-merck-cos-herceptin-biosimilar/

Market Access/ News/ News

Samsung Bioepis’ Humira biosimilar launches in EU

Richard Staines AbbVie, biosimilars, inflammatory diseases, Samsung Bioepis 0 Comment

Samsung Bioepis has become the latest biosimilars company to confirm it has launched a cheaper near-copy of AbbVie’s

Samsung Bioepis’ Humira biosimilar launches in EU

https://pharmaphorum.com/news/samsung-bioepis-humira-biosimilar-launches-in-eu/

Market Access/ News/ News

Merck & Co signs biosimilars deal for US veterans

Joy Persaud biosimilars, inflammatory diseases, market access, Merck & Co, Samsung Bioepis 0 Comment

Merck & Co has signed a deal with the US Department of Veterans Affairs (VA) for its inflammatory

Merck & Co signs biosimilars deal for US veterans

https://pharmaphorum.com/news/merck-co-signs-biosimilars-deal-for-us-veterans/

News/ News/ R&D

Samsung Bioepis and Takeda begin first trial from R&D tie-up

Richard Staines R&D, Samsung Bioepis, Takeda 0 Comment

Companies signed risk-sharing deal last year

Samsung Bioepis and Takeda begin first trial from R&D tie-up

https://pharmaphorum.com/news/samsung-bioepis-and-takeda-begin-first-trial-from-rd-tie-up/

AbbVie/ News/ News/ Sales and Marketing/ Sales and Marketing/ UK & Europe/ US

Biogen gets go-ahead for EU Humira launch in October

Richard Staines AbbVie, Biogen, inflammatory diseases, litigation, patent, Samsung Bioepis 0 Comment

But deal with Samsung prevents US launch until mid-2023

Biogen gets go-ahead for EU Humira launch in October

https://pharmaphorum.com/sales-marketing/biogen-gets-go-ahead-eu-humira-launch-october/

Trending

Samsung Bioepis

Login